Sang-kyu Lee
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Journal: Experimental & molecular medicine
Published: June 22, 2018
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Journal: Scientific reports
Published: June 01, 2018
WDR76 is a RAS binding protein that functions as a tumor suppressor via RAS degradation.
Journal: Nature communications
Published: May 23, 2018
β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
Journal: EMBO reports
Published: March 05, 2018
Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling.
Journal: Experimental & molecular medicine
Published: February 19, 2018
Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Journal: Advances in biological regulation
Published: January 06, 2018
KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
Journal: Oncotarget
Published: August 20, 2016
Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.
Journal: Nature chemical biology
Published: June 23, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026